Jenscare Scientific's (HKG:9877) LuX-Valve Plus transvenous tricuspid valve replacement system has received approval from Hong Kong's Department of Health, according to a Friday Hong Kong bourse filing.
The medical device company plans to commercialize the device in Hong Kong, while LuX-Valve Plus has already obtained regulatory approvals in countries and regions across Europe, the Middle East and Asia-Pacific, the filing said.
Shares of the company fell over 2% in recent trade.